Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1171-1174. doi: 10.1051/medsci/2019232. Epub 2020 Jan 6.

[Developability assessment with case studies highlighting the decision taking].

[Article in French; Abstract available in French from the publisher]

Author information

1
Biologics Research/Sanofi R&D, 13 quai Jules Guesde, 94403 Vitry-sur-Seine, France.
2
Biologics Drug Products Development/Sanofi R&D, 13 quai Jules Guesde, 94403 Vitry-sur-seine, France.
3
Integrated Drug Discovery Sanofi, 13 quai Jules Guesde, 94403 Vitry-sur-Seine, France.

Abstract

in English, French

Therapeutic antibodies generation has to be faster with less development costs. This requires combination of in silico predictions associated with cutting edge screening and characterization technologies. Here, non-exhaustive examples illustrate this simultaneity need.

PMID:
31903933
DOI:
10.1051/medsci/2019232

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center